Bring AI-assisted pancreatic CT review to more care settings
We work with imaging centers, screening programs, technology vendors, and distributors worldwide.
Clinically validated AI
92.1% sensitivity for sub-2 cm pancreatic lesions and national multicenter AUC 0.95 — documented in 6 peer-reviewed publications.
Regulatory-ready
TFDA medical device license in Taiwan and U.S. FDA Breakthrough Device Designation — a documented regulatory foundation.
Real-world deployments
Used at Taiwan medical centers, with cumulative use in more than 5,500 patient cases across research and commercial applications. Clinical and third-party validation are documented separately.
Taiwan R&D excellence
Born from National Taiwan University research, with RSNA Margulis Award recognition in 2023 and 10 invention patents in Taiwan and the U.S.
Partnership models
🏥 Radiology & imaging centers
Add pancreatic cancer AI reading to your CT workflow as a value-added service — with integration support for your PACS environment.
🩺 Health checkup & screening programs
Strengthen your health check packages with early pancreatic cancer screening — a documented option for eligible programs.
💻 PACS & HIS vendors
Embed PANCREASaver® as a curated AI application for your existing customer base, with documented integration interfaces.
🌏 Distributors & channel partners
Represent PANCREASaver® in your market with full clinical, regulatory, and marketing support from the PanCAD.ai team.
🔬 Research & academic institutions
Collaborate on real-world data studies, clinical validation, and publications that advance the evidence base together.
Let's explore what we can build together.
Tell us about your organization and goals — our team will respond within two business days.